Evidence map›Paper›PMID 38309729›Full record

ArticleSaudi medical journal2024

Course and predictors of excellent response to therapy in patients with differentiated thyroid cancer at long-term follow-up.

Shaza A Samargandy, Ghofran N Qorban, Arwa K Aljadani, Salihah S Almufarji, Abdulrahman M Azab, Mazin A Merdad, Marwan R Al-Hajeili, Saad J Samargandy

Abstract read
In one paragraph

Article in Saudi medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shaza A SamargandyFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Ghofran N QorbanFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.ORCID https://orcid.org/0009-0004-8786-7674
Arwa K AljadaniFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Salihah S AlmufarjiFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Abdulrahman M AzabFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Mazin A MerdadFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Marwan R Al-HajeiliFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.
Saad J SamargandyFrom the Department of Medicine (A. Samargandy, Qorban, Aljadani, Almufarji, Azab), Endocrinology Unit; form the Department of Otorhinolaryngology (Merdad); from the Department of Medicine (Al-Hajeili), Oncology Unit; and from the Department of Community Medicine (J. Samargandy), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the long-term outcomes of differentiated thyroid cancer (DTC) and the predictive factors for excellent and incomplete responses to therapy on long-term follow-up of patients.

methodsA retrospective chart review and analysis was carried out at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Demographic, histological, and therapeutic data were collected from patients older than 13 years at the time of diagnosis, with a minimum follow-up of 18 months. Outcomes were divided into excellent, indeterminate, biochemically incomplete, and structurally incomplete responses. Odds ratios (ORs) for predictors of incomplete response at the last visit were determined. We first tested associations univariately with incomplete responses, and then variables with significant associations were included in a multivariable logistic model.

resultsAmong 230 patients with DTC, 61.7% had excellent responses to therapy on long-term follow-up, and 24.3% had incomplete biochemical and structural responses. The median follow-up was 4.6 years. Factors significantly associated with incomplete response to therapy in the multivariate analysis (

conclusionWe strongly advocate incorporating age into recurrence risk assessment for patients with DTC.

Indexed as

AdenocarcinomaThyroid NeoplasmsFollow-Up StudiesHumansMiddle AgedPrognosisRetrospective StudiesRisk AssessmentThyroidectomyprognosisresponse to therapysurvivalthyroid cancer

Identifiers

PMID38309729
PMCPMC11115420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.